ATE430935T1 - Nachweis und behandlung von prostatakrebs - Google Patents
Nachweis und behandlung von prostatakrebsInfo
- Publication number
- ATE430935T1 ATE430935T1 AT02742263T AT02742263T ATE430935T1 AT E430935 T1 ATE430935 T1 AT E430935T1 AT 02742263 T AT02742263 T AT 02742263T AT 02742263 T AT02742263 T AT 02742263T AT E430935 T1 ATE430935 T1 AT E430935T1
- Authority
- AT
- Austria
- Prior art keywords
- prostate cancer
- prostate
- detection
- treatment
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
- G01N2405/10—Glycosphingolipids, e.g. cerebrosides, gangliosides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30025001P | 2001-06-21 | 2001-06-21 | |
| PCT/US2002/019851 WO2003000117A2 (en) | 2001-06-21 | 2002-06-21 | Detection and treatment of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE430935T1 true ATE430935T1 (de) | 2009-05-15 |
Family
ID=23158305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02742263T ATE430935T1 (de) | 2001-06-21 | 2002-06-21 | Nachweis und behandlung von prostatakrebs |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7135301B2 (de) |
| EP (1) | EP1410022B1 (de) |
| JP (1) | JP2005514585A (de) |
| AT (1) | ATE430935T1 (de) |
| AU (1) | AU2002315411A1 (de) |
| DE (1) | DE60232244D1 (de) |
| WO (1) | WO2003000117A2 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE430935T1 (de) * | 2001-06-21 | 2009-05-15 | Glycomimetics Inc | Nachweis und behandlung von prostatakrebs |
| PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
| US20110250218A1 (en) | 2008-10-29 | 2011-10-13 | Fong Lawrence H | Disease-Associated Antigens and Methods of Use Thereof |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| DK2678446T3 (en) * | 2011-02-24 | 2017-09-11 | Ventana Med Syst Inc | Presence of erg gene rearrangements and protein overexpression in low-malignant pin (lg-pin) in prostate biopsies |
| KR101645905B1 (ko) | 2012-10-12 | 2016-08-04 | 스피로즌 살 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
| MY171561A (en) | 2012-11-15 | 2019-10-18 | Endocyte Inc | Conjugates for treating diseases caused by psma expressing cells |
| EP2968585B1 (de) | 2013-03-13 | 2018-07-18 | Medimmune Limited | Pyrrolobenzodiazepine und konjugate davon |
| GEP20237479B (en) | 2013-10-18 | 2023-03-27 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP3069147A4 (de) | 2013-11-14 | 2017-10-11 | Endocyte, Inc. | Verbindungen für positronenemissionstomografie |
| WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| JP2019534882A (ja) | 2016-10-11 | 2019-12-05 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 免疫介在性療法薬を有する抗体−薬物コンジュゲート |
| SG11202010217YA (en) | 2018-04-17 | 2020-11-27 | Endocyte Inc | Methods of treating cancer |
| JP2021524449A (ja) | 2018-05-23 | 2021-09-13 | アーデーセー セラピューティクス ソシエテ アノニム | 分子アジュバント |
| US12473265B2 (en) | 2019-05-20 | 2025-11-18 | Endocyte, Inc. | Methods for preparing PSMA conjugates |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2022078524A2 (en) | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863713A (en) * | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| US5227160A (en) * | 1988-07-15 | 1993-07-13 | The Biomembrane Institute | Monoclonal antibody nuh2 capable of inactivating motility of human sperm, antigen defined by said monoclonal antibody and methods of using said monoclonal antibody and antigen |
| JPH11510795A (ja) | 1995-07-14 | 1999-09-21 | グリコテック コーポレイション | Ｅｇｆレセプターに関連する癌の処置のための化合物および方法、ならびにｅｇｆレセプターの精製 |
| ATE430935T1 (de) * | 2001-06-21 | 2009-05-15 | Glycomimetics Inc | Nachweis und behandlung von prostatakrebs |
-
2002
- 2002-06-21 AT AT02742263T patent/ATE430935T1/de not_active IP Right Cessation
- 2002-06-21 WO PCT/US2002/019851 patent/WO2003000117A2/en not_active Ceased
- 2002-06-21 EP EP02742263A patent/EP1410022B1/de not_active Expired - Lifetime
- 2002-06-21 US US10/176,960 patent/US7135301B2/en not_active Expired - Lifetime
- 2002-06-21 AU AU2002315411A patent/AU2002315411A1/en not_active Abandoned
- 2002-06-21 JP JP2003506571A patent/JP2005514585A/ja active Pending
- 2002-06-21 DE DE60232244T patent/DE60232244D1/de not_active Expired - Lifetime
-
2006
- 2006-10-02 US US11/541,830 patent/US7727735B2/en not_active Expired - Lifetime
-
2010
- 2010-04-13 US US12/759,322 patent/US20110027180A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20030096327A1 (en) | 2003-05-22 |
| JP2005514585A (ja) | 2005-05-19 |
| EP1410022B1 (de) | 2009-05-06 |
| US20110027180A1 (en) | 2011-02-03 |
| US7727735B2 (en) | 2010-06-01 |
| US7135301B2 (en) | 2006-11-14 |
| EP1410022A2 (de) | 2004-04-21 |
| DE60232244D1 (de) | 2009-06-18 |
| WO2003000117A3 (en) | 2003-11-13 |
| AU2002315411A1 (en) | 2003-01-08 |
| WO2003000117A2 (en) | 2003-01-03 |
| US20070048809A1 (en) | 2007-03-01 |
| EP1410022A4 (de) | 2005-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE430935T1 (de) | Nachweis und behandlung von prostatakrebs | |
| DE60329165D1 (de) | Detektion und/oder beobachtung von synuclein-assoziierten krankheiten | |
| HUP0302332A2 (hu) | Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére | |
| TR200002784T2 (tr) | Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar | |
| DE69933989D1 (de) | Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten | |
| NO20080361L (no) | Preparater og fremgangsmater for diagnostiseringer og behandlinger av tumor | |
| DE60331921D1 (de) | Diagnose und prävention der krebszellinvasion | |
| TR199902828T2 (xx) | Lizofosfolipidlerin de�i�mi� konsantrasyonlar� ile birle�tirilmi� kanser belirleme y�ntemi. | |
| DE69907151D1 (de) | Krebsbehandlung | |
| DE60310922D1 (de) | Gefitinib (iressa) zur behandlung von krebs | |
| DE60123954D1 (de) | Vorrichtung zum schützen gegen magnetische und elektrische felder | |
| ATE451477T1 (de) | Diagnose und überwachung von hepatozellulärem karzinom | |
| EP1578760A4 (de) | Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren | |
| ATE350662T1 (de) | Markerproteine für prostatakrebs | |
| DE60234958D1 (de) | Psoriasin-expression durch brustepithelzellen | |
| ATE447622T1 (de) | Methoden und zusammensetzungen zur diagnose und behandlung von pseudoxanthoma elasticum und ähnlichen zuständen | |
| DE60144027D1 (de) | 5t4 rna in plasma und serum als marker für neoplastische erkrankungen | |
| ATE397090T1 (de) | Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen | |
| WO2004019875A3 (en) | Non-invasive methods to identify agents for treating pain | |
| O'Neill et al. | The effects of complete decongestive physical therapy treatment on edema reduction, quality of life, and functional ability of persons with upper extremity lymphedema | |
| EP1576349A4 (de) | Molekulare diagnose und prognose von karzinomen | |
| Park et al. | The Suggestion of the clinical application of Sasang Constitutional Diagnosis | |
| UA42589A (uk) | Спосіб діагностики гомеостазу | |
| UA34212A (uk) | Спосіб оцінки результатів лікування хворих на ранні форми сифілісу | |
| Kuritzky | Colon Cancer Screening: Getting the Right Test Done. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |